In the article modern questions of treatment after percutaneous coronary intervention at ischemic heart disease and conducting these patients from the point of view of modern requirements and clinical recommendations are considered. Efficiency of antiaggregant and hypolipidemic therapy in patients with stable CHD who underwent planned DES-stenting of coronary arteries is estimated. Patients with stable angina pectoris (SS) of III-IV functional classes (FC) of the Uzbek population (average age 57.3±6.5 years, duration of the disease on the average 5.4±1.2 years) were under observation. According to the indications, a planned coronaroangiography was performed with subsequent implantation of DES-stents on GE OPTIMA angiography unit (USA). As the results of the study showed, the timely use of modern means to control platelet aggregation, lipid metabolism in the use of basic drugs, which include aspirin, clopidogger, statins, individualized approach, taking into account pharmacogenetic studies to treat patients with CHD undergoing stenting, increases the safety and efficiency of treatment.